662 results on '"Wei, Andrew"'
Search Results
2. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML.
3. How comparable are patient outcomes in the “real-world” with populations studied in pivotal AML trials?
4. Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts
5. Outcomes in Patients With Poor-risk Cytogenetics With or Without TP53 Mutations Treated With Venetoclax and Azacitidine
6. Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers
7. Domestic lending and the pandemic: How does banks’ exposure to COVID-19 abroad affect their lending in the United States?
8. Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes
9. Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia
10. Gender and Professional Networks on Bank Boards
11. Venetoclax–based low intensity therapy in molecular failure of NPM1-mutated AML
12. Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine
13. A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome
14. Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG
15. Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study
16. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)
17. Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41
18. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)
19. Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes
20. Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cells
21. Acute myeloid leukaemia
22. Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia
23. Applying molecular measurable residual disease testing in acute myeloid leukaemia
24. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial
25. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial
26. Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine
27. Genomic subtyping and therapeutic targeting of acute erythroleukemia
28. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
29. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
30. Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial
31. Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status
32. Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies
33. It doesn’t stop at validation: patient reported outcome measures require ongoing and iterative development
34. Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial
35. Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL
36. Azacitidine Monotherapy in Patients With Treatment-Naïve Higher-risk Myelodysplastic Syndrome: A Systematic Literature Review and Meta-analysis
37. Do patients with haematological malignancies suffer financial burden? A cross-sectional study of patients seeking care through a publicly funded healthcare system
38. Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML).
39. Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia
40. An MRD-stratified pediatric protocol is as deliverable in adolescents and young adults as in children with ALL
41. Harnessing the benefits of available targeted therapies in acute myeloid leukaemia
42. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial
43. Sexism, household decisions, and the gender wage gap
44. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial
45. Towards precision medicine for AML
46. Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia
47. Laboratory quality assessment of candidate gene panel testing for acute myeloid leukaemia: a joint ALLG / RCPAQAP initiative
48. Outcomes and health care utilization of older patients with acute myeloid leukemia
49. Clinical MDR1 inhibitors enhance Smac-mimetic bioavailability to kill murine LSCs and improve survival in AML models
50. Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.